Drug Profile
CDP 855
Latest Information Update: 21 Sep 2007
Price :
$50
*
At a glance
- Originator Celltech R&D
- Class Antirheumatics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis; Systemic lupus erythematosus; Transplant rejection
Most Recent Events
- 01 May 2001 Celltech Chiroscience Discovery is now called Celltech R&D
- 02 Feb 2000 Medeva has been merged into Celltech Chiroscience, which is now called Celltech Group
- 22 Oct 1999 Celltech has merged with Chiroscience to form Celltech Chiroscience